122 related articles for article (PubMed ID: 23898070)
21. Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells.
Kuramitsu Y; Wang Y; Taba K; Suenaga S; Ryozawa S; Kaino S; Sakaida I; Nakamura K
Anticancer Res; 2012 Jun; 32(6):2295-9. PubMed ID: 22641665
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691
[TBL] [Abstract][Full Text] [Related]
23. DDX39 acts as a suppressor of invasion for bladder cancer.
Kato M; Wei M; Yamano S; Kakehashi A; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2012 Jul; 103(7):1363-9. PubMed ID: 22494014
[TBL] [Abstract][Full Text] [Related]
24. The Effects of HSP27 on Gemcitabine-Resistant Pancreatic Cancer Cell Line Through Snail.
Zhang S; Zhang XQ; Huang SL; Chen M; Shen SS; Ding XW; Lv Y; Zou XP
Pancreas; 2015 Oct; 44(7):1121-9. PubMed ID: 26348464
[TBL] [Abstract][Full Text] [Related]
25. A G-quadruplex-binding compound shows potent activity in human gemcitabine-resistant pancreatic cancer cells.
Ahmed AA; Marchetti C; Ohnmacht SA; Neidle S
Sci Rep; 2020 Jul; 10(1):12192. PubMed ID: 32699225
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells.
Wu X; Liu Z; Guo K; Ma G; Song S
J Cell Biochem; 2019 Mar; 120(3):4463-4471. PubMed ID: 30367508
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
29. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
30. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
[TBL] [Abstract][Full Text] [Related]
31. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
32. A standardized extract of cultured
Islam S; Kitagawa T; Baron B; Kuhara K; Nagayasu H; Kobayashi M; Chiba I; Kuramitsu Y
Oncol Lett; 2021 Sep; 22(3):654. PubMed ID: 34386076
[TBL] [Abstract][Full Text] [Related]
33. The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells.
Strouch MJ; Milam BM; Melstrom LG; McGill JJ; Salabat MR; Ujiki MB; Ding XZ; Bentrem DJ
Pancreas; 2009 May; 38(4):409-15. PubMed ID: 19142175
[TBL] [Abstract][Full Text] [Related]
34. Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer.
Jung H; Kim JS; Kim WK; Oh KJ; Kim JM; Lee HJ; Han BS; Kim DS; Seo YS; Lee SC; Park SG; Bae KH
Cell Death Dis; 2015 Jan; 6(1):e1606. PubMed ID: 25611381
[TBL] [Abstract][Full Text] [Related]
35. [The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line].
Yao J; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Yang Y
Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):721-6. PubMed ID: 16483481
[TBL] [Abstract][Full Text] [Related]
36. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
[TBL] [Abstract][Full Text] [Related]
37. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
38. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
Kato T; Ono H; Fujii M; Akahoshi K; Ogura T; Ogawa K; Ban D; Kudo A; Tanaka S; Tanabe M
PLoS One; 2021; 16(6):e0252917. PubMed ID: 34111175
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
40. Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells.
Yasui T; Ohuchida K; Zhao M; Cui L; Onimaru M; Egami T; Fujita H; Ohtsuka T; Mizumoto K; Matsumoto K; Tanaka M
Anticancer Res; 2011 Apr; 31(4):1279-87. PubMed ID: 21508376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
